Tag: ESMO 2016
October 11, 2016
Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab
Peregrine Pharmaceuticals, a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies... October 10, 2016
Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® In Advanced Renal Cell Carcinoma
Pfizer today announced data from an ongoing, investigational Phase 1b study of INLYTA® combined with the checkpoint inhibitor pembrolizumab, a... October 10, 2016
TRACON Pharmaceuticals Presents Final Updated Phase 1b Results for TRC105
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet... October 10, 2016
Ipsen and Exelixis Announce Positive Results from Phase 2 CABOSUN Trial
Ipsen and Exelixis today announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously... October 7, 2016
Myriad Announces Four Poster Presentations at the 2016 ESMO Annual Meeting
Myriad Genetics, a leader in molecular diagnostics and personalized medicine, today announced that four poster presentations will be featured at... October 5, 2016
Karyopharm to Present Updated SIGN Phase 2 Clinical Data at ESMO
Karyopharm Therapeutics, a clinical-stage pharmaceutical company, today announced that an oral presentation highlighting updated clinical data from the Company’s ongoing... September 30, 2016